Notice for trastuzumab deruxtecan (AstraZeneca Pty Ltd)
Active ingredients
trastuzumab deruxtecan
Sponsor
Date of review outcome
Lapse date
Type
Priority Review
Indication
For the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen
Therapeutic area
Oncology